Novum’s CJC-1295 without DAC reports name the material Modified GRF (1–29), a 29-residue amidated peptide. The without-DAC qualifier matters: a covalently modified DAC structure and a salt form are separate chemical distinctions.
What the supplied report names
The supplied 5 mg report calls the material Modified GRF (1–29), marketed as CJC-1295 without DAC, and describes a 29-residue amidated peptide. It reports an LC-HRMS identity comparison but does not print the complete amino-acid sequence or full chemical form of its reference.Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)
A published chemical reference, with its boundary
The FDA’s 2024 technical dossier separately defines CJC-1295 free base and CJC-1295 DAC. Its tables provide the following free-base fields. They are reference information, not additional results measured in the supplied Novum report.FDA — CJC-1295 technical identity dossier (2024) (opens in a new tab)Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)
| Field | Reference value |
|---|---|
| CAS number | Not confirmed. Registry entries for 863288-34-0 and 446036-97-1 describe CJC-1295 with DAC, not Modified GRF (1–29), and the supplied report does not print a CAS number. |
| Molecular formula | C152H252N44O42 |
| Molecular weight | 3367.95 g/mol, dossier Table 1 |
| Sequence | Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg–NH2 |
The dossier distinguishes a C-terminal maleimidopropionamide–lysine unit in the DAC form from acetate or trifluoroacetate salt descriptions. A salt name alone therefore does not answer whether DAC is present. Preserve the covalent structure and salt fields separately.FDA — CJC-1295 technical identity dossier (2024) (opens in a new tab)
Resolve the reference before matching identifiers
For the supplied lot, request the complete qualified-reference specification if a sequence or formula match is required. The report’s 29-residue description and identity verdict are useful recorded facts, but neither confirms all details in the published free-base table. Do not silently assign its CAS number to an unspecified salt or to a DAC-bearing structure.Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)FDA — CJC-1295 technical identity dossier (2024) (opens in a new tab)
The certificate separates measured Modified GRF content, chromatographic area purity, water and residual TFA. A residual TFA result is an analytical field; the report does not use it as a complete structural specification.Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)
Product and certificate documents
Sources and further detail
- FDA — CJC-1295 technical identity dossier (2024) (opens in a new tab)
Existing dossier re-read at PDF pages 9–11: Tables 1–2, reference sequence, molecular fields and DAC/salt distinctions only.
- Supplied Modified GRF (1–29) 5 mg report — lot MGF-27-9ZG (opens in a new tab)
Supplied report: identity wording and analytical fields. Results concern the named sample and lot; this is document transcription, not independent authentication.
Identity sources and supplied documents checked for this revision on 3 October 2026. Report transcription is separate from independent authentication. This article has not undergone independent scientific peer review.